![Carole Faig](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Carole Faig
Direktor/Vorstandsmitglied bei
HENRY SCHEIN, INC.
Vermögen: 614 555 $ am 31.05.2026
Profil
Carole T.
Faig currently works at Henry Schein, Inc., as Independent Director from 2023, QuVa Pharma, Inc., as Director, Affinia Therapeutics, Inc., as Independent Director from 2021, Program for Appropriate Technology in Health, as Director from 2022, and The Scan Group, Inc., as Director from 2025.
Ms. Faig also formerly worked at Cue Health, Inc., as Independent Director from 2021 to 2024 and Ernst & Young LLP, as Partner from 1997 to 2020.
Ms. Faig received her undergraduate degree from Sam Houston State University.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
HENRY SCHEIN, INC. 0.01% | 23.03.2026 | 8’025 ( 0.01% ) | 614 555 $ | 31.05.2026 |
Aktive Positionen von Carole Faig
| Unternehmen | Position | Beginn |
|---|---|---|
| HENRY SCHEIN, INC. | Direktor/Vorstandsmitglied | 18.12.2023 |
Affinia Therapeutics, Inc.
 Affinia Therapeutics, Inc. BiotechnologyHealth Technology Develops adeno-associated virus gene therapies | Direktor/Vorstandsmitglied | 01.09.2021 |
QuVa Pharma, Inc.
 QuVa Pharma, Inc. Medical SpecialtiesHealth Technology Manufactures sterile injectable products | Direktor/Vorstandsmitglied | - |
Program for Appropriate Technology in Health
 Program for Appropriate Technology in Health Miscellaneous Commercial ServicesCommercial Services Provides social healthcare services | Direktor/Vorstandsmitglied | 01.12.2022 |
The Scan Group, Inc.
 The Scan Group, Inc. Advertising/Marketing ServicesCommercial Services Provides advertising, digital marketing, graphic design and printing services | Direktor/Vorstandsmitglied | 01.02.2025 |
Ehemalige bekannte Positionen von Carole Faig
| Unternehmen | Position | Ende |
|---|---|---|
| CUE HEALTH INC. | Direktor/Vorstandsmitglied | 24.05.2024 |
Ernst & Young LLP
 Ernst & Young LLP Miscellaneous Commercial ServicesCommercial Services Provides assurance, auditing, tax, legal, technology and consulting & managed services | Corporate Officer/Principal | 01.01.2020 |
Ausbildung von Carole Faig
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
97
Beziehungen ersten Grades
8
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 8 |
|---|---|
Henry Schein, Inc.
 Henry Schein, Inc. Medical DistributorsDistribution Services Distributes healthcare products and services | Distribution Services |
Ernst & Young LLP
Ernst & Young LLP Miscellaneous Commercial ServicesCommercial Services Provides assurance, auditing, tax, legal, technology and consulting & managed services | Commercial Services |
Sam Houston State University
 Sam Houston State University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Program for Appropriate Technology in Health
Program for Appropriate Technology in Health Miscellaneous Commercial ServicesCommercial Services Provides social healthcare services | Commercial Services |
The Scan Group, Inc.
The Scan Group, Inc. Advertising/Marketing ServicesCommercial Services Provides advertising, digital marketing, graphic design and printing services | Commercial Services |
Cue Health, Inc.
 Cue Health, Inc. Medical SpecialtiesHealth Technology Develops a wireless diagnostic device that enables consumers to run clinical lab tests at home to measure their own health | Health Technology |
QuVa Pharma, Inc.
QuVa Pharma, Inc. Medical SpecialtiesHealth Technology Manufactures sterile injectable products | Health Technology |
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Develops adeno-associated virus gene therapies | Health Technology |
